ArticleEmerging infectious diseases2014
Drug-resistant Candida glabrata infection in cancer patients.
Article in Emerging infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.Antimicrobial agents and chemotherapy · 2017Trial
- Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.Nature cancer · 2026Article
- Nanoemulsions With Essential Oils of Piper spp. and Their Antifungal and Cytotoxic Potential.Chemistry & biodiversity · 2026Article
- Clinical pathogen profiles and lung microbiome features in lung infection patients and concurrent cancer: insights from metagenomics next-generation sequencing.Open life sciences · 2026Article
- Antifungal Resistance and Synergistic Therapy in Candida Spp. Isolated From Bottlenose Dolphins Under Human Care: Implications for One Health Management.Veterinary medicine and science · 2025Article
- Role ofCancer pathogenesis and therapy · 2025Review
- Prevalence and molecular basis of resistance to echinocandins among clinical Candida glabrata isolates in Guangdong province, China.BMC microbiology · 2025Article
- Azole resistance: patterns of amino acid substitutions in Candida sterol 14α-demethylase.Antonie van Leeuwenhoek · 2025Article
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Emergence of invasive candidiasis with multipleFrontiers in microbiology · 2025Article
- Nosocomial transmission of fluconazole-resistantMicrobiology spectrum · 2024Article
- Antifungal effect of atorvastatin in comparison with fluconazole onDental research journal · 2024Article
- Review
- Whole-Genome Sequence Analysis ofJournal of fungi (Basel, Switzerland) · 2023Article
- Gel Formulations with an Echinocandin for Cutaneous Candidiasis: The Influence of Azone and Transcutol on Biopharmaceutical Features.Gels (Basel, Switzerland) · 2023Article
- Multiple genome analysis ofMicrobial cell (Graz, Austria) · 2022Article
- Article
- Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata.Microbiology spectrum · 2022Article
- Increasing Incidence and Shifting Epidemiology of Candidemia in Greece: Results from the First Nationwide 10-Year Survey.Journal of fungi (Basel, Switzerland) · 2022Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients are at risk for candidemia, and increasing Candida spp. resistance poses an emerging threat. We determined rates of antifungal drug resistance, identified factors associated with resistance, and investigated the correlation between resistance and all-cause mortality rates among cancer patients with ≥1 C. glabrata-positive blood culture at MD Anderson Cancer Center, Houston, Texas, USA, during March 2005-September 2013. Of 146 isolates, 30 (20.5%) were resistant to fluconazole, 15 (10.3%) to caspofungin, and 10 (6.8%) to multiple drugs (9 caspofungin-resistant isolates were also resistant to fluconazole, 1 to amphotericin B). Independently associated with fluconazole resistance were azole preexposure, hematologic malignancy, and mechanical ventilation. Independently associated with caspofungin resistance were echinocandin preexposure, monocytopenia, and total parenteral nutrition. Fluconazole resistance was highly associated with caspofungin resistance, independent of prior azole or echinocandin use. Caspofungin resistance was associated with increased 28-day all-cause mortality rates. These findings highlight the need for good stewardship of antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.